Search Results
494 items found for "Bcl-2"
- ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships
March 2022 "February 17, 2022 08:00 AM Eastern Standard Time SAN FRANCISCO & SHANGHAI- ShouTi Inc.,
- Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for ...
April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal
- Orion and Peptilogics are pursuing AI-driven drug discovery to explore new functional chemical ...
July 2022 " Orion Biotechnology and Peptilogics are pursuing AI-driven drug discovery to explore new
- Naggie and Rajagopal Elected Members of American Society for Clinical Investigation
March 2022 "March 3, 2022 Susanna Naggie, MD, and Sudarshan Rajagopal, MD, PhD Two School of Medicine Naggie and Rajagopal are two of 95 new members elected to the society for 2022. of American Physicians (AAP), and the American Physician-Scientists Association (APSA) on April 8, 2022
- Targeted Therapies to Reduce Side Effects in Modern Drug Development
December 2021 "Drug development is rarely trivial.
- Drug Discovery Picks Up the Pace, Stays on Target
January 2022 "Voltaire argued, “Perfection is attained by slow degrees; it requires the hand of time
- Therapeutic validation of an orphan G protein-coupled receptor: The case of GPR84
August 2022 "Despite the importance of members of the GPCR superfamily as targets of a broad range of
- Murine bone marrow macrophages and human monocytes do not express atypical chemokine receptor 1
August 2022 "The atypical chemokine receptor 1 (ACKR1) was discovered on erythrocytes as the Duffy blood et al., 1950 ), also called Duffy-antigen/receptor for chemokines, or DARC ( Novitzky-Basso and Rot, 2012 erythroid lineage ACKR1 expression occurs first and is the highest in erythroblasts ( Duchene et al., 2017 Additionally, ACKR1 expression characterizes venular endothelial cells (ECs) ( Pruenster et al., 2009 ; Thiriot et al., 2017 ), including those lining bone marrow (BM) sinusoids ( Duchene et al., 2017 )
- Amgen to Acquire Chemocentryx for $4 Billion in Cash
August 2022 "THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ
- SYnAbs is now officially accredited as a Research Tax Credit by the French Ministry of Higher...
August 2022 "We are proud to announce that SYnAbs is now officially accredited as a Research Tax Credit by the French Ministry of Higher Education and Research for 2022-2023-2024.
- Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares
August 2022 "August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...
August 2022 Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders "Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: subtype B (GABAB) positive allosteric modulator (PAM) drug candidates has been extended until March 31, 2023
- Effects of Small Molecule Ligands on ACKR3 Receptors
August 2022 "Abstract Chemokines such as stromal derived factor 1 and their G protein coupled receptors
- Actions of Parathyroid Hormone Ligand Analogues in Humanized PTH1R Knockin Mice
August 2022 "Abstract Rodent models are commonly used to evaluate parathyroid hormone (PTH) and PTH-related
- X4 slashes pipeline, lays off staff just three weeks after netting a $55M PIPE
July 2022 "Not even a PIPE financing could save X4 Pharmaceuticals from enacting layoffs and trimming afternoon that it would downsize its research to focus on its lead program, mavorixafor, and lay off about 20%
- Dr. Ross Bathgate becomes Scientific co-founder of LASEREDD Therapeutics
July 2022 "I’m happy to share that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics
- Tectonic Therapeutic Strengthens Leadership Team
July 2022 "July 19, 2022 07:00 AM Eastern Daylight Time BOSTON-- Tectonic Therapeutic , Inc. a pre-clinical
- Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for ...
July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases "29/06/2022 Confo Therapeutics , founded in 2015 as a spin-off from VIB and VUB, announced
- Exscientia is 10 years old this July!
July 2022 "Today we are celebrating ten years of Exscientia ! Founded as a spinout from the University of Dundee on 20 July 2012, Exscientia pioneered the design
- Addex raises $4.2 million in equity financing
July 2022 " Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics payable on exercise as well as unregistered warrants to purchase up to 15,000,000 shares in the form of 2,500,000
- Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate ...
July 2022 Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate range of cancers in combination with other immunotherapies Tokyo, Japan, London and Cambridge, UK, 22 July 2022 – Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical
- Third Rock pushes newest fund over $1B line as it marks 15 years in venture capital
June 2022 "June 15, 2022 06:30 AM EDT - In 2016, Abbie Celniker was promoted to partner at Third Rock
- GPCR Therapeutics welcomes Dr. Ed Brennan as their new Vice President, Head of Clinical Development
June 2022 "We’re delighted to welcome Dr Ed Brennan as our new Vice President, Head of Clinical Development In 2007 he formed IndiPharm which was a full-service Contract Research Organization whose operational In 2016 the company was sold to Velocity fund partners and has been rebranded as InClinica .
- Orion Shares New Data on its Latest Best-in-Class Drug Candidate
June 2022 "Ottawa, Canada, May 10, 2022 — Orion Biotechnology Canada Ltd, a drug discovery and development today announced that it will be presenting important new data at both LSX World Congress and TIDES USA 2022 conference, taking place this week – May 10-12, 2022.
- Accelerating GPCR Drug Discovery With Conformation-Stabilizing VHHs
June 2022 "G protein-coupled receptors (GPCRs) represent a major therapeutic target class as they play GPCRs respond to a wide variety of signals that range in size from photons to proteins (Foord et al., 2005 most tractable classes of drug targets and are targeted by 30%–40% of current drugs (Hauser et al., 2017 ), with annual sales of GPCR-targeting drugs in 2018 accounting for >114 billion USD. In 2019, 5 out of 20 first-in-class approved therapeutic agents targeted GPCRs.
- Michel Bouvier appointed Knight of the Ordre national du Québec
June 2022 "Published on juin 22, 2022 On June 22, 2022, Michel Bouvier , Chief Executive Officer of IRIC
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
May 2022 " MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. Vraniak’s career spans more than 20 years of financial and commercial experience in the life sciences enabled immuno-oncology company and led the company through a successful IPO on Nasdaq in February 2021 a key member of the management team that led the company through a successful IPO on Nasdaq in June 2018
- Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR
May 2022 Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal development of new gastrointestinal therapeutics Tokyo, Japan, Cambridge, UK and New York, USA – May 17, 2022